Del Mar Profile

USD 0.027  3.36%
0.8Last Month High 0.98 
0.8Trading Day  High 0.84 

Purchase by Dennis Brown of 3000 shares of Del Mar

Del Mar Pharmaceuticals Inc insider trading alert for perchase of series b preferred stock by Dennis Brown, Chief Scientific Officer, on December 8, 2017. This event was filed by Delmar Pharmaceuticals In with SEC on 2016-05-03. Statement of changes in beneficial ownership - SEC Form 4. Dennis Brown is currently serves as chief scientific officer, director of Del Mar Pharmaceuticals [view details]   

Del Mar Summary

Del Mar Pharmaceuticals Inc (DMPI) is traded on Nasdaq Capital Markets in USA. It is located in BRITISH COLUMBIA, CANADA and employs 4 people. Del Mar is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with current market capitalization of 17.93 M. Del Mar Pharmaceuticals Inc has 21.6 M outstanding shares of which 1.25 M shares are currently shorted by private and institutional investors with about 2.21 trading days to cover. DELMAR PHARMA currently holds about 13.16 M in cash with (8.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.61.
Check Del Mar Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Del Mar Pharmaceuticals Risk Profiles

Key Fundamentals

Del Mar Against Markets

Current Ratings  

Del Mar 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
< 89% 
DelMar Pharmaceuticals, Inc., a clinical stage company, focuses on developing and commercializing anticancer therapies to treat cancer patients who have failed to respond to modern therapy. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameDel Mar Pharmaceuticals Inc
Analyst Consensus
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
Business AddressVancouver, BC VZ K
ExchangeNasdaq Capital Markets
IndustryPharmaceutical Products
Contact Number604 629 5989
CurrencyUSD - US Dollar

Did you try this?

Run Crypto Portfolio Optimizer Now

Crypto Portfolio Optimizer

Optimize portfolio of digital coins and token across multiple currency and exchanges
Hide  View All  NextLaunch Crypto Portfolio Optimizer


Del Mar Analyst Recommendations
Target PriceAdvice# of Analysts
14.84Strong Buy5Odds
Del Mar Pharmaceuticals Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Del Mar Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Del Mar Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.17February 21, 2017
Del Mar Pharmaceuticals Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate